Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1487 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Bethlem Myopathy & Ullrich Congenital Muscular Dystrophy NGS Panel | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Bethlem myopathy 1 (BTHLM1; MIM 158810) and Ullrich congenital muscular dystrophy 1 (UCMD2; MIM 254090) are two related disorders caused by mutations in the COL6A1, COL6A2 or COL6A3 gene. Bethlem myopathy 2 (BTHLM2; MIM 616471) and Ullrich congenital muscular dystrophy 2 (UCMD2; MIM 616470) are caused by mutations in the COL12A1 gene. Bethlem myopathy is an autosomal dominant disorder characterized by mild to moderate proximal muscular weakness and mild muscle atrophy. Contractures of the elbows, ankles, and flexion contractures of the last four fingers are present and range in severity. There may be moderate weakness of the trunk muscles and diaphragm. The age of onset ranges from birth to adulthood. The disorder is slowly progressive and about one half of the patients require ambulatory support after the fifth decade. Ullrich congenital muscular dystrophy was originally described as an autosomal recessive disorder, but heterozygous dominant negative mutations have also been described. Ullrich congenital muscular dystrophy is more severe than Bethlem myopathy and is characterized by neonatal hypotonia, severe muscular weakness, and generalized muscular atrophy. Patients with Ullrich congenital muscular dystrophy have delayed motor milestones and difficulty with ambulation. Patients also present with proximal joint contractures, spinal rigidity, scoliosis, kyphosis, and distal joint laxity. Weakness of the trunk muscles and diaphragm can lead to respiratory insufficiency. Ullrich congenital muscular dystrophy is progressive and many patients lose the ability to ambulate. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| COL12A1, COL6A1, COL6A2, COL6A3 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Neuromuscular | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.